Introduction: Reimbursement decisions on orphan drugs carry significant uncer-
| INTRODUC TI ON
Reimbursement decisions on orphan drugs (ie medicines for treating rare diseases affecting less than 5 in 10 000 people in the European Union 1 ) carry significant uncertainty. 2, 3 Uncertainty typically arises from a lack of high-quality information on (i) clinical benefit, (ii) value for money, (iii) potential adoption/diffusion and (iv) affordability. 4, 5 The natural histories of many rare diseases, which tend to be lifethreatening or severely debilitating, remain poorly understood, and high-quality randomized clinical trials are often difficult to conduct because of small patient populations and limited validated outcome measures. 5, 6 As uncertainty increases, so does the risk of making a "wrong decision." Patients may be harmed and resources may be wasted when a treatment provided turns out to be ineffective or unsafe or when a treatment not provided turns out to be effective. 4 Therefore, to manage risk while enabling access to potentially beneficial drugs, innovative ways of introducing these drugs have been developed, [7] [8] [9] one of which may be referred to as managed access programmes (MAPs). 4 MAPs provide patients with a drug while information needed to address uncertainties is collected to inform a definitive coverage decision. As an outcome-based arrangement, they resemble complex patient access schemes offered through NHS England. 10 In Canada, patients, caregivers and patient organizations have expressed support for MAPs. Further, they perceive their input to be critical to successful implementation, should such a policy option be adopted. However, they have yet to be systematically involved in their design.
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| OBJEC TIVE
The aim of this study was to co-design with patients and caregivers a tool for the development of managed access programmes.
| ME THODS
A participatory action research (PAR) approach was used. PAR requires the active involvement of researchers and participants in co-constructing knowledge; promoting self-and critical awareness (which leads to individual, collective and/or social change); and building alliances for effective planning, implementation and dissemination of the research. 12 In Canada, the Canadian Organization for Rare Disorders (CORD) represents the rare diseases community. It is comprised of more than 80 patient organizations and is recognized as the national voice of this community, advocating for appropriate access to care.
In this study, we built on established relationships between CORD and members of the study team. At the same time, recent research from our group had demonstrated that there was strong interest in the CORD community in a possible role for patients and families in developing innovative approaches, such as MAPs, to improve coverage for orphan and ultra-orphan drugs. 13 Two workshops were held using the methods described below.
| Study population
All patients and caregivers at two CORD Regional Forums were invited to participate in the workshops, which were part of the main Forum programme (ie no other sessions were scheduled at the same time). The Forums focused on strategies for sustainable access to therapies and explored personalized approaches to drug access.
Presentations were made on assessing therapies for real-world use, strategies for responsible use and different pathways for access, including MAPs. Prior to the Forums, participants had participated in two CORD conferences focused on improving access to therapies for rare diseases and efforts to accomplish this in other countries. They also included presentations on the challenges faced by decision-makers in Canada and discussions around the feasibility of applying international experience to the Canadian context. CORD travel grants were provided to patients and families for the conferences and Forums, minimizing financial barriers to attendance.
| Data collection
Workshops built upon findings from research previously undertaken in collaboration with CORD (deliberative discussions with multiple stakeholders and then patients and caregivers, followed by webinars and priority-setting exercises with patients and families) (see Figure S1 in Appendix A for the diagram of research progression).
Questions focused on the 4 main types of uncertainty that decisionmakers face (listed in the Introduction) and sought to elicit information from participants on additional sources of uncertainty and aspects of MAPs important to them (see Table S1 in Appendix A for the list of questions). Two experienced researchers facilitated both workshops, which began with a presentation on MAPs and examples of their use. Both workshops were audio-recorded and transcribed.
No training was provided prior to the workshop, but all of the participants had attended the Forum and CORD conferences.
| Data analysis and interpretation
Transcripts were analysed using a thematic network approach, 14 a tool for organizing the different levels of themes that emerge in a thematic analysis of qualitative data. Transcripts were first coded inductively using open coding methods. 15 Codes were then clustered into "basic themes," describing the premise of the coded data (eg no legitimate drug alternatives). 14 Basic themes focusing on similar issues were further grouped into "organizing themes" (eg drug priorities for MAPs). 14 Finally, organizing themes were grouped into "global themes," capturing what they meant as a whole (eg best practices for an ideal managed access programme). 14 Constant comparative analysis was used to organize codes into themes, 15 which were subsequently mapped onto an uncertainties matrix, reflecting their link to a specific type of uncertainty. Finally, by considering how the themes could be operationalized in the implementation of a MAP, an "ideal" MAP checklist was created similar to commonly used critical appraisal tools. Through the workshops, four global themes reflecting "notions"
| RE SULTS
were identified. A notion is an individual's impression of something known, experienced or imagined 16 The notions related to patients' and caregivers' experiences living with a rare disease and accessing appropriate therapies (eg orphan drugs). Collectively these appeared to guide their views on what they considered a MAP that they felt would provide the necessary, but missing information on a new therapy. In addition to these notions, patients and caregivers also identified specific aspects of an ideal MAP. Overarching the four notions and the aspects of an ideal MAP was "sentiments," capturing why patients valued MAPs and wanted to be involved in their design.
Further details on each notion, including examples from the transcripts, can be found in Appendix A (Tables S2 and S3 ).
| The four notions
The 
| Research on rare diseases and orphan drugs is challenging
Patients and caregivers reiterated the challenges involved in conducting research on rare diseases and orphan drugs, the most significant of which remains the poorly understood natural histories of rare diseases ("Well finally, at least we know I'm not the only one…" -P5, W2) and its impact on the discovery of effective therapies. They emphasized the importance of on-going collection of natural history and clinical outcomes data. They recognized that while registries may play a role, they require significant resources to implement and 
| Challenges around coverage decision-making processes affect access to orphan drugs
Patients and caregivers discussed challenges in Canadian coverage decision-making processes that affect their ability to access orphan drugs. 
| Aspects of an ideal MAP
Additionally, patients' and caregivers' described the components that a MAP should contain. Six aspects of an ideal MAP were identified. In considering how to operationalize these components, a checklist was developed, which organized the aspects into three categories relating to accountability, governance and evidence collection (Table 1 ).
An annotated version of this checklist can be found in Appendix B, which maps the notions onto the checklist components (Table B1 ). 
| Accountability aspects
| Governance aspects
MAP-specific Committee
Patients and caregivers indicated that MAPs should be overseen by a MAP-specific committee with "a stipulation that there's patient representation" (P9, W1) from three patient members who: 1) meet a minimum level of experience within the health-care system, 2) have a meaningful role on the committee and 3) are accountable back to the organization they represent to avoid bias and enhance knowledge translation. To this end, they saw a role for patient organizations in selecting patient representa-
tives who "understand all [their] needs… [to] go on [their] behalf" (P3, W1).
They also agreed that committees should include a physician who specializes in the specific rare disease-"somebody in the med-
ical field who understands [the specific disease]" (P4, W1
) and the patient community should select that physician. Finally, there was a widely held view that committee meetings should be "open to anybody" (P7, W1) so that all patients/caregivers have the opportunity to provide input into the programme. This is discussed in detail below.
Individual patient input
The importance of providing opportunities for individual patient and caregiver input in the development of a MAP was 
| Evidence collection aspects
Outcome measures and continuation criteria
Patients and caregivers believed they should have an opportunity to provide input on the outcome measures selected and used as continuation criteria to ensure they are meaningful. They felt that patients should be asked, "What do you think? What else can you tell us?" (C1, W2). With respect to continuation criteria, where these could not be determined a priori (eg for poorly understood, ultra-rare, heterogeneous diseases), participants felt that decisions around continuation on therapy should be made through a conversation between patients and their physicians (eg "try and up the dose"-P4, W2).
At the same time, the need to "act on the answer" (P1, W2) provided through a MAP was stressed by patients and caregivers.
Where the treatment proves ineffective based on previously agreed outcomes, participants indicated it should be discontinued, with decision-makers enforcing follow-through.
"..so you do have to set schemes up in such a way (1) in hope of getting an answer and (2) that you're going to act on the results in a reasonable kind of way." (C2, W2)
On-going monitoring and registries 
| Disease/drug priorities
Patients and caregivers recognized that health-care resources are finite and that it is infeasible to have a MAP for every drug. As such, they also considered possible disease or drug eligibility criteria for deciding when to use a MAP. They included drugs that treat "life-threatening or chronically debilitating conditions" (P2, W1) and those for which there are no other legitimate alternatives (ie when an alternative exists but is not an option for all patients, eg, due to intolerance). Drugs that are innovative (ie offer a new mechanism of action) or high cost were also seen as priorities. When asked whether disease prevalence alone is a sufficient criterion to make a drug a priority for a MAP, patients and caregivers both responded "no." While there was broad agreement from patients and caregivers on these criteria, some wondered "why we…are even thinking about excluding [drugs] " (P4, W1), arguing that the use of MAPs for all drugs may make the health-care system more efficient.
| The role of MAPs
In addition to the 4 notions described above, 3 overarching "senti- what they would see as success"-P1, W2) and contributing to decisionmaking committees. 10 Those that take the form of a "complex scheme," where pricing and reimbursement is outcome-based, share many of the elements presented in the MAPs checklist.
| D ISCUSS I ON
Additionally, a checklist for evaluating access with evidence development (AED) schemes, which serve a similar purpose to MAPs, has been published. 20 Specifically, AEDs provide interim coverage to patients through participation in a study designed to generate evidence needed to make a definitive coverage decision. The elements are broadly similar to those of the MAPs checklist.
While much of this work focussed on what an ideal MAP
should look like, general discussions around the current context of orphan drug access, the challenges that patients and caregivers face and, ultimately, why MAPs was viewed as an appropriate solution also took place. The three sentiments identified from these discussions (trust, hope and desperation) have been documented in published literature. One study found that patients with lower levels of trust in their physician were more likely to want an autonomous role in treatment decision making. 21 Another study which involved a qualitative analysis of cancer patients' conversations demonstrated that hope often served as a justification for action. 22 Finally, a recent ethics paper argued that it is a combination of desperation and hope that motivates patients with untreatable diseases to drastic measures to find potentially effective therapies. 23 It was also recognized that MAPs will not address all of the issues that patients and families face with respect to managing rare diseases (eg the exclusion of patients and specialists with relevant expertise from committees reviewing submissions for drug coverage or disparities in access to coverage across Canadian provinces and territories). Studies on the reasonableness of patients and their willingness to accept limits have been documented in other studies.
24,25
| Limitations
Both workshops were held at national events hosted by CORD, and it is possible that the individuals who chose to participate in these events were not representative of the rare disease population in Canada. However, CORD is comprised of over 80 different rare disease patient organizations and covers travel expenses for patients and caregivers to attend their events, reducing the likelihood of bias.
| CON CLUS ION
The MAP checklist co-designed by patients and caregivers offers a tool for informing the development and evaluation of such policy options, which aim to improve access to drugs where there is a high degree of uncertainty in the available evidence. Future research is needed to examine the feasibility of this checklist and roles for other stakeholders.
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